Financial Daily from THE HINDU group of publications
Saturday, Jul 31, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Home Page - Financial Performance
Corporate Results - Pharmaceuticals


Ranbaxy net down 6 pc

Our Bureau

New Delhi , July 30

DECLINING sales of antibiotic Cefuroxime Axetil in the US has taken a toll on Ranbaxy Laboratories Ltd. It has resulted in its net profit falling by six per cent during the second quarter of the current financial year to touch Rs 184.95 crore lower than the Rs 196.78 crore registered the previous year.

Total income during the quarter increased to Rs 977.3 crore, up from Rs 897.12 crore recorded last year.

The Ranbaxy Group too showed negative growth with net profit coming down 4.6 per cent to Rs 195.8 crore against Rs 205.3 crore, while its total income increased by 11 per cent to Rs 1,326.7 crorefrom Rs 1,209.4 crore.

For the first six months of the current fiscal, Ranbaxy recorded consolidated sales of Rs 2,565.9 crore, registering a growth of 14 per cent compared to Rs 2,245.1 crore in the same period last year, while the net profit was at Rs 3,86.4 crore.

While the markets of Europe continued to grow, during the second quarter its US operations generated sales of $92 million, a decline of 9 per cent. Sales of Cefuroxime Axetil stood at just $4 million during the second quarter, compared to $36 million recorded during the same period last year.

However, a lower net profit is unlikely to affect the overall performance during 2004, said Dr Brian W. Tempest, Managing Director and CEO.

"We have raised our guidance for the second half of the year and expect it to be much stronger, at over 20 per cent. On net profits, we had predicted a flattish growth during the first half and expect it to be buoyant in the next six months."

He added that the growth would come from the US markets where the company plans to launch several new products.

"We will file for (regulatory) approvals of 25 molecules during the second half, but we have not yet decided how many to launch. We already have approvals for 80 molecules and 40 are awaiting clearances," Dr Tempest added.

More Stories on : Financial Performance | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
US slaps 14.2 pc duty on shrimp from India


IA goes for lower fares on 8 sectors
M.P. Birla sisters join fight against Lodha
Monsoon situation turns from bad to worse
Thailand removes India's misgivings — Coast is clear for free trade pact
Kerry promises sops to keep jobs in US
Ranbaxy net down 6 pc
ITC posts 16 pc rise in Q1 profit at Rs 462 cr
TCS issue gets oversubscribed by 1.43 times on second day
Rs 50 lakh missing from RBI currency consignment



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line